PRED FORTE Rx
Generic Name and Formulations:
Prednisolone acetate 1%; oph. susp; contains benzalkonium chloride, sulfites.
Indications for PRED FORTE:
Adults and Children:
Instill 1–2 drops 2–4 times daily. During the initial 24–48hrs, the dosing frequency may be increased if needed.
Fungal, mycobacterial, viral (except herpes zoster) or untreated bacterial infections.
Corneal or scleral thinning. Glaucoma. Myopia. Diabetes. Asthma. Monitor for secondary infections and intraocular pressure in prolonged use. May mask or exacerbate infections. Avoid abrupt cessation. Re-evaluate if no improvement after 2 days. Pregnancy. Nursing mothers.
Increased intraocular pressure, posterior subcapsular cataract formation, delayed wound healing, corneal perforations, optic nerve damage, defects in visual acuity and fields of vision, allergic reactions, dysgeusia, eye pain, foreign body sensation, headache, others.
Mild—5mL, 10mL; Forte—5mL, 10mL, 15mL
Clinical Pain Advisor Articles
- Chronic Neuropathic Pain Updated Classification by IASP for ICD-11
- Buprenorphine-Naloxone Found to Be More Cost-Effective Than Extended-Release Naltrexone
- Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache
- Meta-Analysis of Opioid Treatment for Chronic Noncancer Pain
- Opioids Found to Increase Risk for Community-Acquired Pneumonia, Particularly in HIV
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- Early Physical Therapy for Musculoskeletal Pain May Reduce Opioid Use
- External Trigeminal Nerve Stimulation May Alleviate Migraine Pain
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Comparable Analgesia With Low-Dose IV Ketamine, Morphine for Acute Pain
- Benzodiazepines, if Prescribed, May Not Affect Methadone Treatment Retention
- When Opioid Prescribing Guidelines Become Rules
- IV Fluid Confers No Significant Treatment Effect on Migraine Pain
- American Headache Society Releases Position Statement on Novel Preventive and Acute Migraine Treatments